HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 07-25-2006, 01:46 PM   #1
R.B.
Senior Member
 
Join Date: Mar 2006
Posts: 1,843
A role for progesterone

I have referred to this previously and just refound where I filed it.

It is interesting in that it suggest that local levels of estradiol were higher in the breast in correlation with higher progesterone.

As this increase was not seen in abdominal tissue this suggest it is being locally produced?

Progesterone is produced in the period post ovulation presumably preparing the body for attachment and growth of the egg.

Have the implications of progesterone in HER2 been explored?

What about ER beta receptors.? "and life span via a receptor (ERbeta)-mediated pathway" What are the implications for a life span mediator.

This is very much beyond beyond my very very very limited BC mechanism knowledge.

I just post it in case it of use to somebody else.

RB






http://www.ncbi.nlm.nih.gov/entrez/q...=pubmed_DocSum



1: J Endocrinol. 2005 Oct;187(1):103-8. Links
Increased extracellular local levels of estradiol in normal breast in vivo during the luteal phase of the menstrual cycle.
• Dabrosin C.
Division of Gynaecologic Oncology, Faculty of Health Sciences, University Hospital, SE-581 85 Linkoping, Sweden. chada@ibk.liu.se
Estrogen exposure is a major risk factor for breast cancer. Tissue estrogen originates from the ovaries but a significant portion is also produced by enzyme activity locally in the breast itself. How these enzymes are regulated is not fully understood. The extracellular space, where the metabolic exchange and cell interactions take place, reflects the environment that surrounds the epithelium but there has been no previous study of hormone concentrations in this compartment. In the present study microdialysis was used to measure extracellular estrogen concentrations in breast tissue and abdominal subcutaneous fat in 12 healthy women in vivo. It was found that women with high plasma progesterone levels had significant increased levels of estradiol in breast tissue compared with fat tissue (breast tissue 168+/-6 pM; subcutaneous fat, 154+/-5 pM; P<0.05), whereas women with low plasma progesterone exhibited no difference. Moreover, there was a significant correlation between local breast tissue estradiol and plasma progesterone levels (r=0.709, P<0.01). There was no difference in estrone sulphate in breast and fat tissue regardless of progesterone levels. Estrone was not detectable. The results in this study suggest that progesterone may be one regulator in the local conversion of estrogen precursors into potent estradiol in normal breast tissue.
PMID: 16214945 [PubMed - indexed for MEDLINE]


1: J Histochem Cytochem. 1999 Oct;47(10):1323-30.Click here to read Links
Murine progesterone receptor expression in proliferating mammary epithelial cells during normal pubertal development and adult estrous cycle. Association with eralpha and erbeta status.

* Zeps N,
* Bentel JM,
* Papadimitriou JM,
* Dawkins HJ.

Urological Research Centre and Clinic, Department of Surgery, University of Western Australia, Queen Elizabeth II Medical Centre, Nedlands, WA, Australia.

The ovarian steroids estrogen and progesterone are important in directing the normal growth and development of the mouse mammary gland. Previously, we have demonstrated that the majority of proliferating mammary epithelial cells do not express estrogen receptor-alpha (ERalpha). In this study we examined the relationship between progesterone receptor (PR) expression and proliferation in mammary epithelial cells using simultaneous immunohistochemistry for progesterone receptor (PR) and tritiated thymidine [(3)H]-Tdr) autoradiography. Results showed that the majority (>80%) of mammary epithelial cells labeled with [(3)H]-Tdr were PR-positive in the terminal end buds (TEBs) of pubertal mice and the ducts of pubertal and adult mice. Whereas the majority of mammary epithelial cells were also PR-positive, the basal cell population, which comprises the minority of mammary epithelial cells in the mammary ducts, was predominantly PR-negative. Nevertheless, the PR-positive phenotype remained the major proliferating cell type in the basal population. These findings suggest that the progesterone signaling pathway is involved in the proliferation of basal cell populations, potentially directing formation of tertiary side branching during pubertal development and alveolar bud formation in adult glands. A proportion of the basal cells exhibited weak expression of ERbeta, suggesting that the role of ERbeta in mediating normal estrogen-induced responses should be further studied. (J Histochem Cytochem: 47:1323-1330, 1999)

PMID: 10490461 [PubMed - indexed for MEDLINE]



1: Endocrinology. 2000 May;141(5):1711-7.Click here to read Links
Expression of estrogen receptor alpha and beta in the rhesus monkey corpus luteum during the menstrual cycle: regulation by luteinizing hormone and progesterone.

* Duffy DM,
* Chaffin CL,
* Stouffer RL.

Division of Reproductive Sciences, Oregon Regional Primate Research Center, Beaverton 97006, USA. duffyd@ohsu.edu

There are conflicting reports on the presence or absence of estrogen receptor (ER) in the primate corpus luteum, and the discovery of a second type of estrogen receptor, ERbeta, adds an additional level of complexity. To reevaluate ER expression in the primate luteal tissue, we used semiquantitative RT-PCR based assays and Western blotting to assess ERalpha and beta messenger RNA (mRNA) and protein levels in corpora lutea (n = 3/stage) obtained from adult female rhesus monkeys at early (days 3-5), mid (days 6-8), mid-late (days 10-12), and late (days 14-16) luteal phase of the natural menstrual cycle. ERalpha mRNA levels did not vary across the stages of the luteal phase, and ERalpha protein was not consistently detected in luteal tissues. However, ERbeta mRNA and protein levels were detectable in early and mid luteal phases and increased (P < 0.05) to peak levels at mid-late luteal phase before declining by late luteal phase. To determine if ERbeta mRNA expression in the corpus luteum is regulated by LH, monkeys received the GnRH antagonist antide either alone or with 3 daily injections of LH to simulate pulsatile LH release. Treatment with antide alone or concomitant LH administration did not alter luteal ERbeta mRNA levels. When monkeys also received the 3beta-hydroxysteroid dehydrogenase inhibitor trilostane to reduce luteal progesterone production, luteal ERbeta mRNA levels were 3-fold higher (P < 0.05) than in monkeys receiving antide + LH only. Replacement of progestin activity with R5020 reduced luteal ERbeta mRNA levels to those seen in animals receiving antide + LH. Thus, there is dynamic ERbeta expression in the primate corpus luteum during the menstrual cycle, consistent with a role for estrogen in the regulation of primate luteal function and life span via a receptor (ERbeta)-mediated pathway. Increased ERbeta expression in the progestin-depleted corpus luteum during LH exposure suggests that the relative progestin deprivation experienced by the corpus luteum between LH pulses may enhance luteal sensitivity to estrogens during the late luteal phase of the menstrual cycle.

PMID: 10803581 [PubMed - indexed for MEDLINE]
R.B. is offline   Reply With Quote
Old 07-25-2006, 02:32 PM   #2
R.B.
Senior Member
 
Join Date: Mar 2006
Posts: 1,843
Another chance encounter - I came across this whilst looking at links on cows milk and oestrogen - which I will post once I have finished it.

RB

http://www.ncbi.nlm.nih.gov/entrez/q...=pubmed_docsum

1: Endocrinology. 2006 Jun 29; [Epub ahead of print]Click here to read Links
Impact of Estrogen Receptor Beta on Gene Networks Regulated by Estrogen Receptor Alpha in Breast Cancer Cells.

* Chang EC,
* Frasor J,
* Komm B,
* Katzenellenbogen BS.

Departments of Molecular and Integrative Physiology, and Cell and Developmental Biology, University of Illinois at Urbana-Champaign, Urbana, IL, 61801; Women's Health and Musculoskeletal Biology, Wyeth Research, Collegeville, PA, 19426.

Two subtypes of the estrogen receptor, ERalpha and ERbeta, mediate the actions of estrogens, and although seventy percent of human breast cancers express ERbeta along with ERalpha, little is known about the possible co-modulatory effects of these two ERs. To investigate this, we have used adenoviral gene delivery to produce human breast cancer (MCF-7) cells expressing different levels of ERbeta, along with their endogenous ERalpha, and have examined the effects of ERbeta and receptor occupancy, using ER subtype selective ligands, on genome-wide gene expression by microarray and pathway network analysis. ERbeta had diverse effects on gene expression, enhancing or counteracting ERalpha regulation for distinct subsets of estrogen target genes. Strikingly, ERbeta in the absence of estradiol (E2), elicited the stimulation or suppression of many genes that were normally only regulated by ERalpha with E2. In addition, ERbeta plus E2 elicited the expression of a unique group of genes that were not regulated by ERalpha plus E2 alone. The expression of genes in many functional categories were modulated by ERbeta, with the greatest numbers associated with transcription factors and signal transduction pathways. Regulation of multiple components in the TGF beta and semaphorin pathways, and of genes controlling cell cycle progression and apoptosis, may contribute to the suppression of cell proliferation observed with ERbeta. Our observations suggest that the relative levels of ERbeta and ERalpha in breast cancers are likely to impact cell proliferation and the activities of diverse signaling pathways and their response to ER ligands and endocrine therapies.

PMID: 16809442 [PubMed - as supplied by publisher]
R.B. is offline   Reply With Quote
Old 07-25-2006, 03:31 PM   #3
Becky
Senior Member
 
Becky's Avatar
 
Join Date: Sep 2005
Location: Stockton, NJ
Posts: 4,179
Rb

The only correlation between progesterone and Her2 (actually the Her/VEGF pathways) that I have found (to include some of this year's ASCO reports) have to do with the fact that the growth receptor pathways downregulate progesterone (usually far more) than estrogen.

Some of the papers and posters this year focused on the triple negative women but did (in 2 posters and one presentation) reference ER+ but PR neg. I did attend these as it is a rarer pathology of which I have.

Being progesterone negative points to being Her+ (1-3 - at least one of them) and also one may be VEGF positive as well. ER+, PR- tend to be Her2+ (a small population is also Her1+). At least 35% of triple negatives are Her1+. More ER-PR- women who are Her2+ are Her1+ versus those that have at least one hormone receptor being positive. You are absolutely less apt to be Her1+ if you are ER and PR positive.

It seems that the progesterone receptor being positive is associated with a much better prognosis than just being ER+ but I think it is due to the fact that the Estrogen receptor likes to crosstalk more than associate with itself so if there is no progesterone receptor, then other pathways HAVE to be involved. Other papers elude that the other pathways shutdown the progesterone receptor. Very complicated.

Thanks for being so dedicated to the Omega 3/6 balance and information. I swear it is why my cancer was so downgraded as I began doing that about 2-3 months prior to diagnosis and continued throughout treatment. I am a true believer.

Kind regards

Becky
Becky is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 02:00 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter